Evaluation of hepatocyte growth factor in iraqi patients with acute myeloid leukemia: Its correlation with clinical parameters and response to induction therapy

Abstract

BACKGROUND: Hepatocyte growth factor (HGF) is a proangiogenic factor that exerts different effects over stem cell survival growth, apoptosis, and adhesion. Its impact on leukemogenesis has been established by many studies. AIM: This study aimed to determine the effect of plasma HGF activity on acute myeloid leukemia (AML) patients at presentation and after remission. PATIENTS AND METHODS: This was a cross-sectional prospective study of 30 newly-diagnosed, adult, and AML patients. All patients received the 7+3 treatment protocol. Patients’ clinical data were taken at presentation, and patients were followed up for 6 months to evaluate the clinical status. Plasma HGF levels were estimated by ELISA based methods in the patients at two intervals first at diagnosis and the 2nd time after remission of disease. Plasma HGF levels were only measured once in twenty healthy control individuals. RESULTS: A statistically significant lowering in the median levels of HGF after remission induction therapy has been found when compared with those before treatment (p = 0.006) and in the group of patients who achieved complete remission in comparison with those before treatment (p = 0.005). Furthermore, a significant reduction was also demonstrated after treatment in patients presenting with extramedullary involvement (p = 0.003) and in the alive group (p = 0.001). CONCLUSION: Plasma HGF estimation can be a useful parameter in predicting treatment outcomes in patients with AML, and it can add potentially useful information to risk stratification parameters.